VYGR (Voyager Therapeutics) E10: $0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VYGR Voyager Therapeutics Inc VYGR
55 GF Score
Price $3.27
GF Value $1.67
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Voyager Therapeutics E10?

Voyager Therapeutics VYGR +5.14% 55 E10 is $0.00 as of Jun. 2026. GuruFocus rates VYGR with a GF Score™ of 55/100 and a GF Value™ of $1.67 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Voyager Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was $-0.400. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.00 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-08), Voyager Therapeutics's current stock price is $3.27. Voyager Therapeutics's E10 for the quarter that ended in Jun. 2026 was $0.00. Voyager Therapeutics's Shiller PE Ratio of today is .


Voyager Therapeutics  (NAS:VYGR) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Voyager Therapeutics E10 Related Terms


Voyager Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Voyager Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics E10 Chart

Voyager Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.38 -1.32

Voyager Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.31 -1.33 -1.32 -1.36 0.00

VYGR vs NERV, DTIL, GLSI: E10 Comparison

For the Biotechnology subindustry, Voyager Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Shiller PE Ratio falls into.


VYGR
55GF Score
Voyager Therapeutics Inc VYGR
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyager Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Voyager Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.4/333.9520*333.9520
=-0.400

Current CPI (Jun. 2026) = 333.9520.

Voyager Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201609 -0.350 241.428 -0.484
201612 -0.570 241.432 -0.788
201703 -0.650 243.801 -0.890
201706 -0.730 244.955 -0.995
201709 -0.890 246.819 -1.204
201712 -0.400 246.524 -0.542
201803 -0.630 249.554 -0.843
201806 -0.800 251.989 -1.060
201809 -0.630 252.439 -0.833
201812 -0.700 251.233 -0.930
201903 -0.810 254.202 -1.064
201906 0.290 256.143 0.378
201909 -0.410 256.759 -0.533
201912 -0.340 256.974 -0.442
202003 -0.660 258.115 -0.854
202006 -0.230 257.797 -0.298
202009 2.270 260.280 2.913
202012 -0.430 260.474 -0.551
202103 -0.580 264.877 -0.731
202106 -0.800 271.696 -0.983
202109 -0.670 274.310 -0.816
202112 0.150 278.802 0.180
202203 -0.560 287.504 -0.650
202206 -0.500 296.311 -0.564
202209 0.450 296.808 0.506
202212 -0.610 296.797 -0.686
202303 2.940 301.836 3.253
202306 -0.510 305.109 -0.558
202309 -0.590 307.789 -0.640
202312 1.190 306.746 1.296
202403 -0.200 312.332 -0.214
202406 -0.180 314.175 -0.191
202409 -0.160 315.301 -0.169
202412 -0.590 315.605 -0.624
202503 -0.530 319.799 -0.553
202506 -0.570 322.561 -0.590
202509 -0.470 324.800 -0.483
202512 -0.470 324.054 -0.484
202603 -0.470 330.213 -0.475
202606 -0.400 333.952 -0.400

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $0.00 mean?
Voyager Therapeutics (VYGR) has a E10 of $0.00 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Voyager Therapeutics and its competitors.
Is Voyager Therapeutics' E10 too high?
Voyager Therapeutics' current E10 is $0.00. Overall, Voyager Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' E10 compare to NERV and DTIL?
Voyager Therapeutics' E10 of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current E10 is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (VYGR) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.67, compared to a current price of $3.27 — trading 95.8% above its estimated fair value. The current E10 is $0.00. Voyager Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Voyager Therapeutics (VYGR), the current E10 is $0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (VYGR) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of $3.27 is trading 95.8% above its estimated GF Value™ of $1.67. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for VYGR:

  • E10: $0.00
  • GF Value™: $1.67 vs. price of $3.27 (95.8% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the VYGR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Voyager Therapeutics Business Description

Other Exchanges VYGR:MexicoVT6:Germany
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
55GF Score

Get the complete analysis for VYGR

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.27
Price
$1.67
GF Value